Extensive surface protein profiles of extracellular vesicles from cancer cells may provide diagnostic signatures from blood samples

Journal of Extracellular Vesicles

Volumn 5, Issue 1, 2016, Pages

  Belov, Larissa ^a   Matic, Kieran J ^a   Hallal, Susannah ^a   Best, O Giles ^a,b   Mulligan, Stephen P ^a,b   Christopherson, Richard I ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

Author keywords

CD antigen; chronic lymphocytic leukaemia; exosomes; luminescence; microvesicles

Indexed keywords

ALPHA3 INTEGRIN; CD19 ANTIGEN; CD82 ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; DECAY ACCELERATING FACTOR; EPITHELIAL CELL ADHESION MOLECULE; HERMES ANTIGEN; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA DR ANTIGEN; L SELECTIN; MEMBRANE PROTEIN; PLATELET ENDOTHELIAL CELL ADHESION MOLECULE 1;

AGED; ANIMAL CELL; ANTIBODY SPECIFICITY; ARTICLE; BIOLOGICAL FUNCTIONS; BLOOD ANALYSIS; CANCER CELL; CHEMOLUMINESCENCE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; EXOSOME; FEMALE; HUMAN; HUMAN CELL; LIM1215 CELL LINE; MEC-1 CELL LINE; MEMBRANE MICROPARTICLE; NONHUMAN; PROTEIN ANALYSIS; VERY ELDERLY;

EID: 85010207500     PISSN: None     EISSN: 20013078     Source Type: Journal    
DOI: 10.3402/jev.v5.25355     Document Type: Article

References (76)

1. D'Souza-Schorey C, Clancy JW. Tumor-derived microvesicles: shedding light on novel microenvironment modulators and prospective cancer biomarkers. Genes Dev. 2012; 26: 1287–99.
2. Taylor DD, Gercel-Taylor C. Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects. Br J Cancer. 2005; 92: 305–11. [PubMed Abstract] [PubMed CentralFull Text].
3. Cai J, Han Y, Ren H, Chen C, He D, Zhou L, etal. Extracellular vesicle-mediated transfer of donor genomic DNA to recipient cells is a novel mechanism for genetic influence between cells. J Mol Cell Biol. 2013; 5: 227–38.
4. Choi DS, Kim DK, Kim YK, Gho YS. Proteomics, transcriptomics and lipidomics of exosomes and ectosomes. Proteomics. 2013; 13: 1554–71.
5. Inal JM, Fairbrother U, Heugh S. Microvesiculation and disease. Biochem Soc Trans. 2013; 41: 237–40.
6. Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular organelles important in intercellular communication. J Proteomics. 2010; 73: 1907–20.
7. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. 2013; 200: 373–83.
8. Thery C. Exosomes: secreted vesicles and intercellular communications. F1000 Biol Rep. 2011; 3: 15.
9. Cocucci E, Meldolesi J. Ectosomes and exosomes: shedding the confusion between extracellular vesicles. Trends Cell Biol. 2015; 25: 364–72.
10. Camussi G, Deregibus MC, Tetta C. Tumor-derived microvesicles and the cancer microenvironment. Curr Mol Med. 2013; 13: 58–67.
11. Kucharzewska P, Belting M. Emerging roles of extracellular vesicles in the adaptive response of tumour cells to microenvironmental stress. J Extracell Vesicles. 2013; 2: 20304. http://dx.doi.org/10.3402/jev.v2i0.20304.
12. An T, Qin S, Xu Y, Tang Y, Huang Y, Situ B, etal. Exosomes serve as tumour markers for personalized diagnostics owing to their important role in cancer metastasis. J Extracell Vesicles. 2015; 4: 27522. http://dx.doi.org/10.3402/jev.v4.27522 [PubMed Abstract].
13. Tatischeff I. Cell-derived extracellular vesicles open new perspectives for cancer research. Cancer Res Front. 2015; 1: 208–24.
14. Webber J, Yeung V, Clayton A. Extracellular vesicles as modulators of the cancer microenvironment. Sem Cell Dev Biol. 2015; 27–34.
15. Nicholas J. A new diagnostic tool with the potential to predict tumor metastasis. J Natl Cancer Inst. 2013; 105: 371–2.
16. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. Cancer J Clin. 2014; 64: 9–29.
17. Ghosh AK, Secreto CR, Knox TR, Ding W, Mukhopadhyay D, Kay NE. Circulating microvesicles in B-cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood. 2010; 115: 1755–64.
18. Chiorazzi N, Ferrarini M. B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. Annu Rev Immunol. 2003; 21: 841–94.
19. Seifert M, Sellmann L, Bloehdorn J, Wein F, Stilgenbauer S, Durig J, etal. Cellular origin and pathophysiology of chronic lymphocytic leukemia. J Exp Med. 2012; 209: 2183–98.
20. Belov L, Mulligan SP, Barber N, Woolfson A, Scott M, Stoner K, etal. Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray. Br J Haematol. 2006; 135: 184–97.
21. Ellmark P, Belov L, Huang P, Lee CS, Solomon MJ, Morgan DK, etal. Multiplex detection of surface molecules on colorectal cancers. Proteomics. 2006; 6: 1791–802.
22. Kaufman KL, Belov L, Huang P, Mactier S, Scolyer RA, Mann GJ, etal. An extended antibody microarray for surface profiling metastatic melanoma. J Immunol Methods. 2010; 358: 23–34.
23. Zhou J, Belov L, Huang PY, Shin JS, Solomon MJ, Chapuis PH, etal. Surface antigen profiling of colorectal cancer using antibody microarrays with fluorescence multiplexing. J Immunol Methods. 2010; 355: 40–51.
24. Kanada M, Bachmann MH, Hardy JW, Frimannson DO, Bronsart L, Wang A, etal. Differential fates of biomolecules delivered to target cells via extracellular vesicles. Proc Natl Acad Sci USA. 2015; 112: E1433–42. [PubMed Abstract] [PubMed CentralFull Text].
25. Lötvall J, Hill AF, Hochberg F, Buzás EI, Di Vizio D, Gardiner C, etal. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J Extracell Vesicles. 2014; 3: 26913. http://dx.doi.org/10.3402/jev.v3.26913.
26. Oksvold MP, Kullmann A, Forfang L, Kierulf B, Li M, Brech A, etal. Expression of B-cell surface antigens in subpopulations of exosomes released from B-cell lymphoma cells. Clin Ther. 2014; 36: 847–62 e1.
27. Saunderson SC, Schuberth PC, Dunn AC, Miller L, Hock BD, MacKay PA, etal. Induction of exosome release in primary B cells stimulated via CD40 and the IL-4 receptor. J Immunol. 2008; 180: 8146–52.
28. Whitehead RH, Macrae FA, John DJBS, Ma J. A colon cancer cell line (LIM1215) derived from a patient with inherited nonpolyposis colorectal cancer. J Natl Cancer Inst. 1985; 74: 759–65. [PubMed Abstract].
29. Stacchini A, Aragno M, Vallario A, Alfarano A, Circosta P, Gottardi D, etal. MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res. 1999; 23: 127–36.
30. Logozzi M, De Milito A, Lugini L, Borghi M, Calabro L, Spada M, etal. High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients. PLoS One. 2009; 4: 5219. http://dx.doi.org/10.1371/journal.pone.0005219.
31. Thery C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006. Chapter 3:Unit 3.22, doi: http://dx.doi.org/10.1002/0471143030.
32. Colino J, Snapper CM. Dendritic cell-derived exosomes express a Streptococcus pneumoniae capsular polysaccharide type 14 cross-reactive antigen that induces protective immunoglobulin responses against pneumococcal infection in mice. Infect Immun. 2007; 75: 220–30.
33. Lai RC, Tan SS, Teh BJ, Sze SK, Arslan F, de Kleijn DP, etal. Proteolytic potential of the MSC exosome proteome: implications for an exosome-mediated delivery of therapeutic proteasome. Int J Proteomics. 2012; 2012: 971907.
34. Li J, Lee Y, Johansson HJ, Mager I, Vader P, Nordin JZ, etal. Serum-free culture alters the quantity and protein composition of neuroblastoma-derived extracellular vesicles. J Extracell Vesicles. 2015; 4: 26883. http://dx.doi.org/10.3402/jev.v4.26883 [PubMed Abstract].
35. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, etal. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines. Blood. 2008; 111: 5446–56.
36. Belov L, Huang P, Barber N, Mulligan SP, Christopherson RI. Identification of repertoires of surface antigens on leukemias using an antibody microarray. Proteomics. 2003; 3: 2147–54.
37. Belov L, de la Vega O, dos Remedios CG, Mulligan SP, Christopherson RI. Immunophenotyping of leukemias using a cluster of differentiation antibody microarray. Cancer Res. 2001; 61: 4483–9. [PubMed Abstract].
38. Ellmark P, Woolfson A, Belov L, Christopherson RI. The applicability of a cluster of differentiation monoclonal antibody microarray to the diagnosis of human disease. Methods Mol Biol. 2008; 439: 199–209. [PubMed Abstract].
39. Hamelinck D, Zhou H, Li L, Verweij C, Dillon D, Feng Z, etal. Optimized normalization for antibody microarrays and application to serum-protein profiling. Mol Cell Proteomics. 2005; 4: 773–84.
40. Zhou J, Belov L, Armstrong N, Christopherson RI. Antibody microarrays and multiplexing. Bioinform Hum Proteomics. 2013; 3: 331–59.
41. Sedlmayr P, Leitner V, Pilz S, Wintersteiger R, Stewart CC, Dohr G. Species-specific blocking of Fc-receptors in indirect immunofluorescence assays. Laboratory Hematol. 2001; 7: 81–4.
42. Lacroix R, Judicone C, Poncelet P, Robert S, Arnaud L, Sampol J, etal. Impact of pre-analytical parameters on the measurement of circulating microparticles: towards standardization of protocol. J Thromb Haemost. 2012; 10: 437–46.
43. Mullier F, Bailly N, Chatelain C, Chatelain B, Dogne JM. Pre-analytical issues in the measurement of circulating microparticles: recommendations and pending questions. J Thromb Haemost. 2013; 11: 693–6.
44. Gardiner C, Ferreira YJ, Dragovic RA, Redman CW, Sargent IL. Extracellular vesicle sizing and enumeration by nanoparticle tracking analysis. J Extracell Vesicles. 2013; 2: 19671. http://dx.doi.org/10.3402/jev.v2i0.19671.
45. Huang PY, Kohnke P, Belov L, Best OG, Mulligan SP, Christopherson RI. Profiles of surface mosaics on chronic lymphocytic leukemias distinguish stable and progressive subtypes. J Pharm Pharm Sci. 2013; 16: 231–7. [PubMed Abstract].
46. Molica S, Mauro FR, Giannarelli D, Lauria F, Cortelezzi A, Brugiatelli M, etal. Differentiating chronic lymphocytic leukemia from monoclonal B-lymphocytosis according to clinical outcome: on behalf of the GIMEMA chronic lymphoproliferative diseases working group. Haematologica. 2011; 96: 277–83.
47. Dürig J, Naschar M, Schmücker U, Renzing-Köhler K, Hölter T, Hüttmann A, etal. CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. Leukemia. 2002; 16: 30–5.
48. Zhou J, Belov L, Solomon MJ, Chan C, Clarke SJ, Christopherson RI. Colorectal cancer cell surface protein profiling using an antibody microarray and fluorescence multiplexing. J Vis Exp. 2011; 55: 3322. http://dx.doi.org/10.3791/3322 [PubMed Abstract].
49. de Jong OG, Verhaar MC, Chen Y, Vader P, Gremmels H, Posthuma G, etal. Cellular stress conditions are reflected in the protein and RNA content of endothelial cell-derived exosomes. J Extracell Vesicles. 2012; 1: 18396. http://dx.doi.org/10.3402/jev.v1i0.18396.
50. Escola JM, Kleijmeer MJ, Stoorvogel W, Griffith JM, Yoshie O, Geuze HJ. Selective enrichment of tetraspan proteins on the internal vesicles of multivesicular endosomes and on exosomes secreted by human B-lymphocytes. J Biol Chem. 1998; 273: 20121–7.
51. Ji H, Greening DW, Barnes TW, Lim JW, Tauro BJ, Rai A, etal. Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components. Proteomics. 2013; 13: 1672–86.
52. Nazarenko I, Rana S, Baumann A, McAlear J, Hellwig A, Trendelenburg M, etal. Cell surface tetraspanin Tspan8 contributes to molecular pathways of exosome-induced endothelial cell activation. Cancer Res. 2010; 70: 1668–78.
53. Perez-Hernandez D, Gutierrez-Vazquez C, Jorge I, Lopez-Martin S, Ursa A, Sanchez-Madrid F, etal. The intracellular interactome of tetraspanin-enriched microdomains reveals their function as sorting machineries toward exosomes. J Biol Chem. 2013; 288: 11649–61.
54. Greening DW, Ji H, Kapp EA, Simpson RJ. Sulindac modulates secreted protein expression from LIM1215 colon carcinoma cells prior to apoptosis. Biochim Biophys Acta. 2013; 1834: 2293–307.
55. Gutierrez LS. The role of thrombospondin 1 on intestinal inflammation and carcinogenesis. Biomark Insights. 2008; 3: 171–8. [PubMed Abstract] [PubMed CentralFull Text].
56. Jayachandran A, Anaka M, Prithviraj P, Hudson C, McKeown SJ, Lo PH, etal. Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma. Oncotarget. 2014; 5: 5782–97.
57. Miyata Y, Sakai H. Thrombospondin-1 in urological cancer: pathological role, clinical significance, and therapeutic prospects. Int J Mol Sci. 2013; 14: 12249–72.
58. Sutton CD, O'Byrne K, Goddard JC, Marshall LJ, Jones L, Garcea G, etal. Expression of thrombospondin-1 in resected colorectal liver metastases predicts poor prognosis. Clin Cancer Res. 2005; 11: 6567–73.
59. Niederfellner G, Lammens A, Mundigl O, Georges GJ, Schaefer W, Schwaiger M, etal. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood. 2011; 118: 219–20.
60. Haderk F, Hanna B, Richter K, Schnolzer M, Zenz T, Stilgenbauer S, etal. Extracellular vesicles in chronic lymphocytic leukemia. Leuk Lymphoma. 2013; 54: 1826–30.
61. Paggetti J, Haderk F, Seiffert M, Janji B, Kim YJ, Diestler U, etal. Chronic lymphocytic leukemia-exosomes switch endothelial and mesenchymal stroma cells into cancer-associated fibroblasts to sustain leukemic cell survival. Blood. 2014; 124: 2927.
62. Burgess M, Gill D, Singhania R, Cheung C, Chambers L, Renyolds BA, etal. CD62L as a therapeutic target in chronic lymphocytic leukemia. Clin Cancer Res. 2013; 19: 5675–85.
63. Zucchetto A, Sonego P, Degan M, Bomben R, Dal Bo M, Bulian P, etal. Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance. J Transl Med. 2006; 4: 11.
64. Vlad A, Deglesne P-A, Letestu R, Saint-Georges S, Chevallier N, Baran-Marszak F, etal. Down-regulation of CXCR4 and CD62L in chronic lymphocytic leukemia cells is triggered by B-cell receptor ligation and associated with progressive disease. Cancer Res. 2009; 69: 6387–95.
65. Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, etal. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014; 371: 213–23.
66. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, etal. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014; 370: 997–1007.
67. Aung T, Chapuy B, Vogel D, Wenzel D, Oppermann M, Lahmann M, etal. Exosomal evasion of humoral immunotherapy in aggressive B-cell lymphoma modulated by ATP-binding cassette transporter A3. Proc Natl Acad Sci USA. 2011; 108: 15336–41.
68. Paggetti J, Haderk F, Seiffert M, Janji B, Distler U, Ammerlaan W, etal. Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells into cancer-associated fibroblasts. Blood. 2015; 126: 1106–17.
69. Caivano A, Laurenzana I, De Luca L, La Rocca F, Simeon V, Trino S, etal. High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders. Tumor Biol. 2015; 1–14.
70. Jakobsen KR, Paulsen BS, Bæk R, Varming K, Sorensen BS, Jørgensen MM. Exosomal proteins as potential diagnostic markers in advanced non-small cell lung carcinoma. J Extracell Vesicles. 2015; 4: 26659. http://dx.doi.org/10.3402/jev.v4.26659 [PubMed Abstract].
71. Tesselaar ME, Romijn FP, Van Der Linden IK, Prins FA, Bertina RM, Osanto S. Microparticle-associated tissue factor activity: a link between cancer and thrombosis?. J Thromb Haemost. 2007; 5: 520–7.
72. Moreno A, Lucena C, Lopez A, Garrido JJ, Perez de la Lastra JM, Llanes D. Immunohistochemical analysis of ß3 integrin (CD61): expression in pig tissues and human tumors. Histol Histopathol. 2002; 17: 347–52.
73. Saalbach A, Wetzel A, Haustein U-F, Sticherling M, Simon JC, Anderegg U. Interaction of human Thy-1 (CD 90) with the integrin αvβ3 (CD51/CD61): an important mechanism mediating melanoma cell adhesion to activated endothelium. Oncogene. 2005; 24: 4710–20.
74. Seurynck-Servoss SL, White AM, Baird CL, Rodland KD, Zangar RC. Evaluation of surface chemistries for antibody microarrays. Anal Biochem. 2007; 371: 105–15.
75. Hong CS, Muller L, Boyiadzis M, Whiteside TL. Isolation and characterization of CD34+ blast-derived exosomes in acute myeloid leukemia. PLoS One. 2014; 9: 103310. http://dx.doi.org/10.1371/journal.pone.0103310.
76. Keerthikumar S, Gangoda L, Liem M, Fonseka P, Atukorala I, Ozcitti C, etal. Proteogenomic analysis reveals exosomes are more oncogenic than ectosomes. Oncotarget. 2015; 6: 15375.